| P50 | author | María Fernanda Pascutti | Q55136512 |
| | María Paula Del Médico Zajac | Q57782014 |
| | Juliana Falivene | Q89280974 |
| | Andrea Bruttomesso | Q89280976 |
| | Maria Belen Vecchione | Q41160868 |
| P2093 | author name string | Gabriela Calamante | |
| | Cynthia Maeto | |
| | María Magdalena Gherardi | |
| | María Pía Holgado | |
| | Micaela Amigo | |
| P2860 | cites work | Generation of CD8 T cell memory is regulated by IL-12. | Q51973127 |
| | Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor. | Q54381288 |
| | Preparation of cell cultures and vaccinia virus stocks. | Q55076619 |
| | Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine | Q57569666 |
| | The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl) | Q66849845 |
| | Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation | Q79213173 |
| | Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors | Q24303448 |
| | Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa | Q24647137 |
| | IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation | Q24649009 |
| | Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells | Q24651232 |
| | Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C | Q27306437 |
| | NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses | Q27861101 |
| | Host-reactive CD8+ memory stem cells in graft-versus-host disease | Q28281894 |
| | Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome | Q28389050 |
| | Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice | Q30973875 |
| | Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines | Q33210436 |
| | Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya | Q33294698 |
| | Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). | Q33320536 |
| | The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus | Q33782803 |
| | The vaccinia virus superoxide dismutase-like protein (A45R) is a virion component that is nonessential for virus replication. | Q33844429 |
| | Novel mucosal DNA-MVA HIV vaccination in which DNA-IL-12 plus cholera toxin B subunit (CTB) cooperates to enhance cellular systemic and mucosal genital tract immunity | Q34172564 |
| | Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein | Q34182371 |
| | IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12_BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality | Q34289072 |
| | Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens | Q34465228 |
| | The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses | Q34469355 |
| | Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses. | Q34594898 |
| | Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways | Q34796206 |
| | Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles. | Q34991112 |
| | Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. | Q35150010 |
| | Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathway | Q35151746 |
| | The biology of IL-12: coordinating innate and adaptive immune responses | Q35209127 |
| | Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins | Q35488175 |
| | Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery | Q35551800 |
| | Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta | Q35615827 |
| | Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity | Q35656345 |
| | Modified vaccinia Ankara: potential as an alternative smallpox vaccine | Q35823036 |
| | Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection | Q36370370 |
| | Antiviral innate immunity pathways. | Q36394971 |
| | Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques | Q36397581 |
| | Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence | Q36403362 |
| | IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells | Q36694205 |
| | CD8+ T cell efficacy in vaccination and disease | Q37184070 |
| | Clinical development of MVA-based therapeutic cancer vaccines | Q37259579 |
| | Innate immunity to virus infection. | Q37361448 |
| | A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. | Q37421291 |
| | Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. | Q37643731 |
| | Prime-boost vectored malaria vaccines: progress and prospects | Q37671502 |
| | MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. | Q37689057 |
| | TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development | Q37803061 |
| | Regulation of effector and memory T-cell functions by type I interferon | Q37841676 |
| | Clinical development of Modified Vaccinia virus Ankara vaccines | Q38092470 |
| | Clinical applications of attenuated MVA poxvirus strain. | Q38156198 |
| | Truncation of gene F5L partially masks rescue of vaccinia virus strain MVA growth on mammalian cells by restricting plaque size. | Q39074830 |
| | One-step simple assay to determine antigen-specific cytotoxic activities by single-color flow cytometry | Q39546386 |
| | Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine | Q39589039 |
| | Characterization of DNA and MVA vectors expressing Nef from HIV-1 CRF12_BF revealed high immune specificity with low cross-reactivity against subtype B. | Q39806689 |
| | Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara | Q40506182 |
| | Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates | Q40779546 |
| | Effect of 3-beta-hydroxysteroid dehydrogenase gene deletion on virulence and immunogenicity of different vaccinia viruses and their recombinants. | Q41012022 |
| | Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine | Q41039759 |
| | Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells | Q41064284 |
| | Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line | Q41076591 |
| | A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope | Q42610963 |
| | Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara | Q42637410 |
| | Poxvirus vectors | Q44509221 |
| | Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes | Q44639419 |
| | Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion | Q45373249 |
| | Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. | Q45421530 |
| | Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes | Q45731710 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P921 | main subject | Vaccinia virus | Q1986297 |
| | vector-borne disease | Q2083837 |
| P577 | publication date | 2016-05-23 | |
| P1433 | published in | Viruses | Q7935305 |
| P1476 | title | Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses | |
| P478 | volume | 8 | |